Iambic Therapeutics’ Post

Did you catch the latest issue of Drug Discovery World? In this insightful issue, Megan Thomas sat down with leading figures in the drug discovery field to explore the hottest trends and most promising areas for investment in 2024. From the potential of artificial intelligence to the growing importance of personalized medicine, there's no shortage of exciting developments on the horizon. But what are the biggest challenges facing the industry? And how can we overcome them to bring life-saving drugs to patients faster? Josh Ludwig, Global Director, Commercial Operations at ScaleReady, weighs in on the conversation on pages 8-9 here: https://lnkd.in/d5AAYUpu #cellandgenetherapy #CGT #healthinnovation #medtech

NEW: Terray Therapeutics becomes the latest AI-focused biotech startup to raise a megaround, just closing a $120 million Series B round. Founding CEO Jacob Berlin, PhD told me his Los Angeles-area biotech aims to enter the clinic in 2026 with its first drug candidate. In the meantime, they will keep scaling a massive dataset of protein-ligand binding interactions. Today that data is 50x larger than what's publicly available, he said, and he believes this is the "key dataset missing for AI-driven drug discovery." “Every single molecule we bring forward has a scaffold that has been de novo discovered and optimized at Terray from the ground up,” Berlin told me. “That’s totally different than what you see across the ecosystem, where AI models have to stay close to historical sets of data because they don’t have our hardware innovation.” My latest exclusive for Endpoints News, including some details on how they developed a partial latent diffusion model to generate new small molecules:

📰 Unlock the Future of Drug Discovery with Syntekabio’s Exclusive Newsletter! 📰 Step into the future with Syntekabio, where AI meets drug discovery in ways never before imagined. Our innovative approaches are not just keeping up with the industry—they’re setting new standards. Subscribe today to keep your finger on the pulse of cutting-edge developments that could change the way you approach R&D. 🌟 Why Subscribe? ➡ Exclusive Insights: Gain insider access to our cutting-edge programs, including our game-changing offer where we invest in your success, with Develop Now, Pay Later. ➡ In-Depth Articles: Dive into comprehensive articles that explore the latest breakthroughs and trends in AI and drug discovery. ➡ Early Access to New Opportunities: Stay ahead with the first look at new offerings, including our complimentary feasibility testing and customized AI solutions to accelerate your R&D. 📩 Don’t miss this chance to enhance your expertise and stay at the forefront of innovation. Subscribe to our newsletter today and be part of the future of drug discovery. https://lnkd.in/eXC4EuiF #AI #DrugDiscovery #healthcareinnovation #Pharma #machinelearning #oncology

AI has a data problem: there's too little quality biological data to keep up with validation and training of advanced drug discovery models. In his talk today, Matt Beaudet shared critical insights to answer one of the most crucial questions in drug discovery today, pointing to the power of ultra-fast cell imaging and analysis to bridge the gap between digital models and real-world therapeutics. Catch Matt and our team at DDIF today and tomorrow—we’d love to connect and share our vision for the future of drug discovery! #DDIF #DDIF2024 #drugdiscovery #techbio #aidrugdiscovery #ai

Tomorrow! Do not miss the chance! Let's talk about the different approaches and how to choose the best one for your project when it comes to immuno-oncology drug testing. #AACR #SITC #immunotherapy #immunooncology #organoids #mousemodels #womeninbio #preclinical

𝗪𝗵𝗮𝘁 𝗮𝗿𝗲 𝟱 𝗺𝗮𝗶𝗻 𝘂𝘀𝗲𝘀 𝗼𝗳 𝗢𝗿𝗴𝗮𝗻-𝗼𝗻-𝗖𝗵𝗶𝗽 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝘁𝗵𝗲 𝗳𝗶𝗲𝗹𝗱 𝗼𝗳 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲? At Bi/ond we believe that every person is unique, and our medicines should reflect this as well. That is why we aim to make personalized medicine a reality by 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝗹𝗮𝗯 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝘁𝗼 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝘁𝗵𝗲 𝗿𝗲𝗰𝗿𝗲𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗺𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗵𝗲𝗮𝗹𝘁𝗵𝘆 𝗮𝗻𝗱 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝗱 𝘁𝗶𝘀𝘀𝘂𝗲 𝘁𝘆𝗽𝗲𝘀 𝗳𝗼𝗿 𝗺𝗼𝗿𝗲 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲 𝗱𝗿𝘂𝗴 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝘀𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀. If you are involved in disease modeling, drug development, biomarker discovery, or patient-specific treatment, then consider partnering with us and using organ-on-chip to advance your research efforts. Find out more : https://lnkd.in/ge6jJBm #organonchip #personalizedmedicine #diseasemodeling #drugdevelopment #gobiond

Sharing data from Dealroom.co showing the GenAI Health landscape with 2024 deal sizes spanning from $15mil - 100m in size. Not seeing the larger deals (yet), but Q2/3 tends to be the most active period for bigger investments. We will be tracking progress monthly via our #AIAccelerator ---> https://lnkd.in/egnuFPiD Snapshot of the top deals in drug discovery AI: 💊 DeepCure $200m valuation and working on biotechnology to drive faster drug discovery - April 2024 💊 Hippocratic AI $500m valuation, working on first-safety focused LLM for healthcare - March 2024 💊 Curve Therapeutics $320m valuation, working on redefining drug discover for efficiency - Feb 2024 💊 Moonwalk Biosciences $274m valuation, focused on precise epigenetic solutions, mapping cellular states at genome level - Jan 2024 #dayonestrategy #genai #drugdiscovery

🔍 Big News in AI-Powered Drug Discovery: Exscientia Merges with Recursion! 🤖💊 In a strategic move that caps off a challenging year for Exscientia, the AI-driven drug discovery company is merging into Recursion, creating a powerhouse in the biotech space! 🌟 Key Highlights: -Combined Strengths: Exscientia brings precision chemistry design and automated synthesis, while Recursion offers scaled biology exploration and translational capabilities. 🧬🤝 -Financial Powerhouse: The new entity will have $850M in cash, $200M in expected milestones over 24 months, and a potential $20B in future royalties. 💰 -Robust Pipeline: With 10 clinical readouts expected over the next 18 months, this merger sets the stage for groundbreaking developments in oncology, rare diseases, and infectious diseases. 🦠🎯 -Synergies & Growth: The companies project $100M in operational synergies, leveraging their combined AI and drug discovery platforms. 📈 This merger signifies a bold step forward in AI-driven biotech, with the potential to revolutionise the development of life-saving medicines. Exciting times ahead! 🚀 #Biotech #AIDrugDiscovery #PharmaInnovation #MergersAndAcquisitions #Oncology #PrecisionMedicine #AI #DrugDevelopment #HealthcareTransformation

Discover the power of #AI in #drugdiscovery: faster candidate identification, reduced lab costs, and accelerated timelines, all made possible by advanced computing solutions with Amgen and Terray Therapeutics. https://bit.ly/3YkRUXE

In drug discovery, preclinical & clinical development, it's important to get the maximum information from your precious samples. Whether they're fresh, fixed or archived tissues, expensive model organisms, or critical patient biopsies. It's amazing to see the work being done using 10x Genomics single cell and spatial technologies in BioPharma to maximise information gained throughout devlopment, in order minimise late stage failures during clinical trials and increase drug success rates. #drugdevelopment #drugdiscovery #clinicaltrials